A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

ABP 501 [United States: AMJEVITA™ (adalimumab-atto); European Union: AMGEVITA(®) (adalimumab)] is the first approved biosimilar to adalimumab [reference product (RP)], a monoclonal antibody (mAb) targeting tumor necrosis factor-alfa (TNF-α). ABP 501 has received approval for use in indications that...

Descripción completa

Detalles Bibliográficos
Autores principales: Markus, Richard, McBride, Helen J., Ramchandani, Monica, Chow, Vincent, Liu, Jennifer, Mytych, Dan, Fanjiang, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822859/
https://www.ncbi.nlm.nih.gov/pubmed/31183781
http://dx.doi.org/10.1007/s12325-019-00979-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822859/
https://www.ncbi.nlm.nih.gov/pubmed/31183781
http://dx.doi.org/10.1007/s12325-019-00979-6

Ejemplares similares